Stock Scorecard



Stock Summary for Autolus Therapeutics plc (AUTL) - $2.35 as of 8/12/2026 8:59:44 AM EST

Total Score

9 out of 30

Safety Score

36 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AUTL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AUTL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AUTL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AUTL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AUTL (36 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for AUTL

Autolus Raises Year-End Outlook as Aucatzyl Sales Accelerate 8/11/2026 6:12:00 PM
Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum 8/11/2026 2:24:00 PM
Form 8K Autolus Therapeutics plc For: 11 August By Investing.com 8/11/2026 2:12:00 PM
Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings 8/11/2026 2:11:00 PM
Autolus Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary 8/11/2026 1:11:00 PM
Form 8K Autolus Therapeutics plc For: 11 August By Investing.com 8/11/2026 12:11:00 PM
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates 8/11/2026 11:11:00 AM
Autolus shares rise 3% on Q2 beat, raised revenue guidance 8/11/2026 11:11:00 AM
Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL 8/10/2026 5:43:00 AM
Autolus Therapeutics plc (AUTL) Stock Analysis: Biotechnology Innovator with 333% Potential Upside 8/8/2026 9:12:00 AM

Financial Details for AUTL

Company Overview

Ticker AUTL
Company Name Autolus Therapeutics plc
Country N/A
Description Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date 8/11/2026

Stock Price History

Last Day Price 2.35
Price 4 Years Ago 1.90
Last Day Price Updated 8/12/2026 8:59:44 AM EST
Last Day Volume 7,659,598
Average Daily Volume 1,749,823
52-Week High 2.52
52-Week Low 1.18
Last Price to 52 Week Low 99.15%

Valuation Measures

Trailing PE N/A
Industry PE 42.59
Sector PE 49.78
5-Year Average PE -3.42
Free Cash Flow Ratio 4.80
Industry Free Cash Flow Ratio 37.74
Sector Free Cash Flow Ratio 109.34
Current Ratio Most Recent Quarter 5.80
Total Cash Per Share 0.49
Book Value Per Share Most Recent Quarter 5.91
Price to Book Ratio 3.67
Industry Price to Book Ratio 6.08
Sector Price to Book Ratio 8.84
Price to Sales Ratio Twelve Trailing Months 493.54
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 24.40
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 266,143,000
Market Capitalization 625,436,050
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -30.61%
Reported EPS 12 Trailing Months -1.09
Reported EPS Past Year -0.27
Reported EPS Prior Year -1.08
Net Income Twelve Trailing Months -288,834,491
Net Income Past Year -288,199,915
Net Income Prior Year -220,662,000
Quarterly Revenue Growth YOY 83,655.00%
5-Year Revenue Growth 113.21%
Operating Margin Twelve Trailing Months -6,571.00%

Balance Sheet

Total Cash Most Recent Quarter 130,925,000
Total Cash Past Year 104,132,000
Total Cash Prior Year 227,380,000
Net Cash Position Most Recent Quarter 130,925,000
Net Cash Position Past Year 104,132,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 178,129,000
Total Stockholder Equity Prior Year 427,325,000
Total Stockholder Equity Most Recent Quarter 108,826,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -322,563,494
Free Cash Flow Per Share Twelve Trailing Months -1.21
Free Cash Flow Past Year -310,700,000
Free Cash Flow Prior Year -241,090,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal -0.03
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 2.00
RSI 61.89
50-Day SMA 1.54
150-Day SMA 2.88
200-Day SMA 2.77

System

Modified 8/11/2026 5:58:06 PM EST